Sanford Guide To Antimicrobial Therapy 2022 (Spiral Bound
The Sanford Guide to Antimicrobial Therapy 2022 (52nd edition)
- 5 x 8 inches (Spiral Edition)
- ISBN: 9781944272203
- Font Size: 8pt (approx)
Available in print in pocket size, spiral bound and large library editions.
The 52nd edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information. Helpful in day-to-day practice and as a component of your organization's antimicrobial stewardship program, The Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, The Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.
- Clinical syndromes
- Anti-infective agents
- pediatric adjustments
- renal adjustments
- adverse effects
- Preventative therapy
What's new in 2022
Numerous changes throughout, with major changes in the following areas:
- New Drugs - Addition of new COVID-19 drugs, cefiderocol, ibrexafungerp, brincidofovir, cabotegravir, doravirine, and more.
- New Tables - ECMO Drug Dosing Adjustment (Table 10F) and QTc Prolongation (Table 10G).
- Table 1: Initial Choice of Antimicrobial Therapy - Numerous changes including 2021 CDC STI updates, recommendations for resistant infections.
- Table 5: Recommendations for MDR Bacteria - Updates for gram-negative bacilli updated based on recent evidence and IDSA Guidelines.
- Table 12: Treatment of Mycobacterial Infections - Revised recommendations for latent M. tuberculosis & non-tuberculous mycobacteria.
- Table 13: Treatment of Parasitic Infections - Significant changes to amebic meningoencephalitis, babesiosis and trypanosomiasis, and updates to sources for antiparasitic drugs (Table 13D).
- Table 14: Treatment of Viral Infections - Updates to COVID-19 treatment recommendations (digital subscriptions have most recent updates)
NOTICE: This year's guide is printed on thicker off-white paper due to supply chain issues.